SEC File
Number: 0-9314
CUSIP
Number:00431M 20 9
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X]
Form 10-Q [ ] Form
N-SAR [ ] Form N-CSR
For
Period Ended: March 31,
2008
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For
the Transition Period Ended:
Read
attached instruction sheet before preparing form. Please print or type. Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates
__________________________________
PART I --
REGISTRANT INFORMATION
Full Name
of
Registrant: Access
Pharmaceuticals, Inc.
Former
Name if Applicable:
Address
of Principal Executive
Office
(Street and number): 2600
Stemmons Freeway, Suite 176
City,
state and zip
code: Dallas,
Texas 75207
PART II
- -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the
following
should be completed. (Check box if appropriate)
[ X ] (a)
The reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
[ X ] (b)
The subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due date; or the subject
quarterly report of transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date;
and
[ ]
(c) The accountant's statement or other exhibit required by Rule
12b-25(c)
has been attached if applicable.
PART III
- -- NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q,
N-SAR, N-CSR or the transition report or portion thereof, could not be filed
within the prescribed time period.
SEE
ATTACHMENT A.
PART IV
- -- OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification:
Stephen
B.
Thompson 214 905-5100
------------------------- ---------- ----------
(Name)
(Area Code) (Telephone Number)
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no, identify report(s).
[
X ] Yes [ ] No
(3) Is it
anticipated that any significant change in for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof? If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of results cannot be made.
[ ] Yes [ X
] No
Access
Pharmaceuticals, Inc.
-----------------------------
(Name of
Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
By: /s/
Stephen B. Thompson
------------------------
Date May
15, 2008
Stephen
B. Thompson, Vice President, Chief Financial Officer and
Principal
Accounting Officer
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be
filed
with the form.
<PAGE>
ATTACHMENT
A
PART III
- -- NARRATIVE
The
registrant experienced delays in completing the Form 10-Q due to the reporting
of merger. As a result the registrant was unable to complete and file the Form
10-Q by the prescribed filing date without unreasonable effort and expense. The
registrant will file the Form 10-Q before the extended deadline.